[Biomarkers in inflammatory bowel disease].

Biomarcadores en enfermedad inflamatoria intestinal: ¿sabe cómo utilizarlos?

Journal

Revista medica de Chile
ISSN: 0717-6163
Titre abrégé: Rev Med Chil
Pays: Chile
ID NLM: 0404312

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 01 08 2019
accepted: 02 01 2020
entrez: 31 7 2020
pubmed: 31 7 2020
medline: 22 9 2020
Statut: ppublish

Résumé

Biomarkers in inflammatory bowel disease are an essential tool in clinical practice. They allow a non-invasive evaluation of patients and thus guide decision-making at different stages of the disease, including diagnostic suspicion, severity assessment, relapse prediction, and treatment response. Although biomarkers in blood such as erythrocyte sedimentation rate and C-reactive protein, are the most commonly used biomarkers, because their low cost and accessibility, they lack specificity. Currently, fecal biomarkers offer greater reliability, applicability, and specificity. Fecal calprotectin is the most commonly used marker. This review discusses the advantages and disadvantages of biomarkers in inflammatory bowel disease, as well as their clinical applications and new biomarkers currently under research.

Identifiants

pubmed: 32730381
pii: S0034-98872020000300362
doi: 10.4067/S0034-98872020000300362
pii:
doi:

Substances chimiques

Biomarkers 0
Leukocyte L1 Antigen Complex 0

Types de publication

Journal Article Review

Langues

spa

Sous-ensembles de citation

IM

Pagination

362-370

Auteurs

Edith Pérez de Arce (E)

Departamento de Medicina Interna, Servicio de Gastroenterología, Hospital Clínico Universidad de Chile, Santiago, Chile.

Rocío Sedano (R)

Departamento de Medicina Interna, Servicio de Gastroenterología, Hospital Clínico Universidad de Chile, Santiago, Chile.

Rodrigo Quera (R)

Programa Enfermedad Inflamatoria Intestinal, Servicio de Gastroenterología, Clínica Las Condes, Santiago, Chile.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH